Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trial
Official title:
A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
The purpose of this study is to determine whether PF-04958242 is safe and effective in the treatment of cognitive dysfunction in schizophrenia subjects
This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05686239 -
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
|
Phase 2 |